Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Ahn JH, da Silva Pedrosa M, Lopez LR, Tibbs TN, Jeyachandran JN, Vignieri EE, Rothemich A, Cumming I, Irmscher AD, Haswell CJ, Zamboni WC, Yu YA, Ellermann M, Denson LA, Arthur JC. Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease. Cell Host Microbe. 2025 Jan 8;33(1):71-88.e9. doi: 10.1016/j.chom.2024.11.012

Jacobson EU, Hicks KA, Carrico J, Purcell DW, Green TA, Mermin JH, Farnham PG. Optimizing HIV prevention efforts to achieve EHE incidence targets. J Acquir Immune Defic Syndr. 2022 Apr;89(4):373-80. doi: 10.1097/QAI.0000000000002885

Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-7. doi: 10.1097/QAI.0000000000002075

Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, Weinrib R, Mansfield C. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):394-403. doi: 10.1097/QAI.0000000000001945.

Khurana N, Yaylali E, Farnham PG, Hicks KA, Allaire BT, Jacobson E, Sansom SL. Impact of improved HIV care and treatment on PrEP effectiveness in the United States, 2016–2020. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):399-405. doi: 10.1097/QAI.0000000000001707